Review
doi: 10.1016/j.gtc.2004.02.004.
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
Affiliations
- PMID: 15177535
- DOI: 10.1016/j.gtc.2004.02.004
Item in Clipboard
Review
Treatment of inflammatory bowel disease with azathioprine and 6-mercaptopurine
Gastroenterol Clin North Am.
2004 Jun.
Abstract
6-Mercaptopurine and azathioprine have become important therapeutic options for patients with inflammatory bowel disease (IBD). Although accumulating data in the literature have supported the use of these immunomodulators in the management of IBD, marked variation exists in the pattern of clinical practice regarding azathioprine or 6-mercaptopurine therapy in patients with IBD. This article provides a critical review of the data on the clinical efficacy and toxicities of 6-mercaptopurine and azathioprine in the management of IBD. Emerging literature on the potential application of pharmacogenetic testing and metabolite monitoring are also discussed.
Similar articles
-
A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate.Am J Gastroenterol. 1996 Mar;91(3):423-33. Am J Gastroenterol. 1996. PMID: 8633486 Review. No abstract available.
-
Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in IBD.Rev Gastroenterol Disord. 2003;3 Suppl 1:S30-8. Rev Gastroenterol Disord. 2003. PMID: 12684587
-
A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease.J Clin Nurs. 2007 Aug;16(8):1427-34. doi: 10.1111/j.1365-2702.2006.01670.x. J Clin Nurs. 2007. PMID: 17655530
-
[Therapy of chronic inflammatory bowel diseases with azathioprine, 6-mercaptopurine and 6-thioguanine. Clinico-pharmacologic aspects].Dtsch Med Wochenschr. 2003 Feb 21;128(8):378-85. doi: 10.1055/s-2003-37378. Dtsch Med Wochenschr. 2003. PMID: 12594624 Review. German. No abstract available.
-
Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.Am J Gastroenterol. 1993 Jan;88(1):44-8. Am J Gastroenterol. 1993. PMID: 8420272
Cited by
-
Azathioprine in the management of enteropathy in cystic fibrosis.J R Soc Med. 2011 Jul;104 Suppl 1(Suppl 1):S40-3. doi: 10.1258/jrsm.2011.s11107. J R Soc Med. 2011. PMID: 21719892 Free PMC article. No abstract available.
-
Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease.World J Gastroenterol. 2008 Sep 28;14(36):5512-8. doi: 10.3748/wjg.14.5512. World J Gastroenterol. 2008. PMID: 18810768 Free PMC article. Review.
-
Immunosuppressive therapies adversely affect blood biochemical parameters in patients with inflammatory bowel disease: a meta-analysis.J Int Med Res. 2019 Aug;47(8):3534-3549. doi: 10.1177/0300060519864800. Epub 2019 Jul 31. J Int Med Res. 2019. PMID: 31364448 Free PMC article.
-
Efficacy of 6-mercaptopurine treatment after azathioprine hypersensitivity in inflammatory bowel disease.World J Gastroenterol. 2008 Jul 21;14(27):4342-6. doi: 10.3748/wjg.14.4342. World J Gastroenterol. 2008. PMID: 18666323 Free PMC article.
-
Assessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative data.Patient. 2013;6(4):241-55. doi: 10.1007/s40271-013-0031-2. Patient. 2013. PMID: 24127239 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
